Main description:

This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.

Contents:

.-1 Resistance of Cancer Stem Cells to Cell-mediated Immune Responses

.-2 Role of Co-inhibitory Molecules in Tumor Escape from CTL attack

.-3 Role of the Non-classical HLA Class I Antigens for Immune Escape

.-4 Integrins: Friends or Foes of Antitumor Cytotoxic T Lymphocyte Response

.-5 Cytotoxic T Lymphocytes and Their Granzymes: An Overview

.-6 Hypoxia: A Formidable Saboteur of the Anti-tumor Response

.-7 Mechanisms and Modulation of Tumor Microenvironment-Induced Immune Resistance

.-8 Evasion of Cytotoxic Lymphocyte and Pulmonary Macrophage Mediated Immune Responses in Lung Cancer

.-9 Sensitization of Immune-Resistant Tumor Cells to CTL-mediated Apoptosis via Interference at the Dysregulated NF- B/Snail/YY1/PI3K/RKIP/PTEN Resistant Loop

.-10 Overcoming Cancer Cell Resistance to Death Receptor Targeted Therapies

.-11 Pancreatic Cancer Resistance to TRAIL Therapy: Regulators of the Death Inducing Signaling Complex

.-12 Resistance of Carcinoma Cells to CTL-mediated Immunotherapy

.-13 Cancer Induced Immunosuppression and its Modulation by Signal Inhibitors

.-14 Quality of CTL Therapies: A Changing Landscape